TrialDiabetes, obesity & metabolism2018

Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study.

Shin-Ichi Harashima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.